App-Quantinova.ai

THE CHARACTERISTICS, TREATMENT PATTERNS, AND SURVIVAL OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATED BY GRAALL OR GRAAPH PROTOCOL

Fatma Kammoun - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

Imatinib

A KINASE-DEAD VARIANT OF CDK6 IS ASSOCIATED WITH REDUCED TUMORIGENIC POTENTIAL AND A DISTINCT TRANSCRIPTIONAL REWIRING IN AN ALL MODEL

Thorsten Klampfl - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

MUTATIONAL LANDSCAPE IN THERAPY-RELATED ACUTE LYMPHOBLASTIC LEUKEMIA

Kevin D. Hofer - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

ADHERENCE TO TREATMENT OF HEMATOLOGICAL MALIGNANCIES PATIENTS WITH ANXIETY AND DEPRESSION

Dmitry E Vybornykh - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

THE TESTICULAR NICHE OF ACUTE LYMPHOBLASTIC LEUKEMIA – MOLECULAR AND CELLULAR FACTORS FOR THE PREFERENTIAL MIGRATION AND SURVIVAL

Tessa Skroblyn - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

CXCL12

REAL WORLD DATA OUTCOMES IN A SINGLE MEXICAN PUBLIC INSTITUTION. ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH NEWLY DIAGNOSED OF ACUTE LYMPHOBLASTIC LEUKEMIA :COMPARATIVE RESULTS OF DIFFERENT PROTOCOLS

Guillermo Sotomayor Duque - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

ONCOGENIC DEUBIQUITINATION CONTROLS TYROSINE KINASE SIGNALING AND THERAPY RESPONSE IN ACUTE LYMPHOBLASTIC LEUKEMIA

Panagiotis Ntziachristos - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

AZACITIDINE AS TREATMENT OF KMT2A INFANT ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER EXPERIENCE

Giovanna Giagnuolo - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Vidaza

IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION

Grzegorz Basak - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

N/A

NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.

Renato Bassan - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

Pegaspargase

PREGNANCIES IN YOUNG ADULTS WITH A HISTORY OF ACUTE LYMPHOBLASTIC LEUKEMIA IN ITALY. A CAMPUS ALL SURVEY.

Fabio Giglio - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

IMAGE-BASED HIGH-CONTENT DRUG SENSITIVITY SCREENING IDENTIFIES CONVENTIONAL, EMERGING, AND POTENTIAL NOVEL THERAPEUTIC TARGETS IN HIGH-RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA

Hayden Bell - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

N/A

PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY

Elias Jabbour - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Ponatinib

TELOMERE LENGTH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

Elena Vakonaki - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

IS NATIVE E-COLI OR PEG-ASPERAGINASE FORMULATION A HIGHER RISK FOR VTE DEVELOPMENT IN PATIENTS WITH POST TREATMENT ACUTE LYMPHOBLASTIC LEUKEMIA? A META-ANALYSIS

Jack T Seki - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Asparaginase

A PROGNOSTIC MODEL TO PREDICT MORTALITY IN ICU DEPARTMENT OF HEMATOLOGY CLINIC

Alexander Luchinin - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

GENETIC CHARACTERISTICS AND CD7-CAR-T THERAPY OF TRAD::MYC TRANSLOCATION POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Tong Wang - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN MEDICAID PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE

Saurabh Aggarwal - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

IMBALANCES IN HOMOCYSTEINE METABOLISM AND LEUKEMIA

Nouha Bouayed Abdelmoula - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

PROGNOSTIC SIGNIFICANCE OF ACTIVIN A IN ADULT EGYPTIAN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.

Mohamed Azzazi - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

N/A

Filters

2187 Abstracts